UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial

Diabetes, obesity & metabolism, 2015-03, Vol.17 (3), p.268-275

2015

Volltextzugriff (PDF)

Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes

The journal of clinical endocrinology and metabolism, 2021-12, Vol.106 (12), p.3497-3504

2021

Volltextzugriff (PDF)

Rosiglitazone decreases albuminuria in type 2 diabetic patients

Kidney international, 2007-12, Vol.72 (11), p.1367-1373

2007

Volltextzugriff (PDF)

Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects

The journal of clinical endocrinology and metabolism, 2011-06, Vol.96 (6), p.1763-1770

2011

Volltextzugriff (PDF)

O1 Mode d’action de l’exénatide sur la réduction des glycémies post-prandiales dans le diabète de type 2

Diabetes & metabolism, 2008, Vol.34, p.H9-H9

2008

Volltextzugriff (PDF)

Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus

Expert opinion on pharmacotherapy, 2015-12, Vol.16 (18), p.2819-2833

2015

Volltextzugriff (PDF)

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

Diabetologia, 2001-12, Vol.44 (12), p.2210-2219

2001

Volltextzugriff (PDF)

Exenatide Exerts Its Positive Effects on Liver by Reducing both Hepatic and Adipose Tissue Insulin Resistance

Journal of hepatology, 2016, Vol.64 (2), p.S171-S171

2016

Volltextzugriff (PDF)

Metabolic effects of muraglitazar in type 2 diabetic subjects

Diabetes, obesity & metabolism, 2011-10, Vol.13 (10), p.893-902

2011

Volltextzugriff (PDF)

Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects

Diabetes/metabolism research and reviews, 2011-05, Vol.27 (4), p.373-382

2011

Volltextzugriff (PDF)

Insulin Secretion is a Strong Predictor for Need of Insulin Therapy in Patients With New Onset Diabetes and HbA1c >10%, a post hoc analysis of EDICT study

Diabetes, obesity & metabolism, 2021-05, Vol.23 (7), p.1631-1639

2021

Volltextzugriff (PDF)

T2DM Subgroups and Response to Glucose-lowering Therapy: Results from EDICT and Qatar Study

Metabolism, clinical and experimental, 2022-03, Vol.128, p.155094, Article 155094

2022

Volltextzugriff (PDF)

Stoffwechselvorgänge beim Anstieg der Ketonkörper im Plasma unter Dapagliflozin

Diabetologie und Stoffwechsel, 2017, Vol.12 (S 01), p.S1-S84

2017

Volltextzugriff (PDF)

Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus

American journal of physiology: endocrinology and metabolism, 2002-12, Vol.283 (6), p.E1135-E1143

2002

Volltextzugriff (PDF)

PS072 - Exenatide Exerts Its Positive Effects on Liver by Reducing both Hepatic and Adipose Tissue Insulin Resistance

Journal of hepatology, 2016, Vol.64 (2), p.S171-S171

2016

Volltextzugriff (PDF)

T2DM Subgroups and Response to Glucose-lowering Therapy: Results from EDICT and Qatar Study

Diabetes, obesity & metabolism, 2022-05

2022

Volltextzugriff (PDF)

New and Emerging Therapies for Type 2 Diabetes

MD conference express, 2014-10, Vol.14 (26), p.21-23

2014

Volltextzugriff (PDF)

Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: Potential New Therapies for Type 2 Diabetes Mellitus

Pharmacotherapy, 2006-03, Vol.26 (3), p.360-374

2006

Volltextzugriff (PDF)

Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the E fficacy and D urability of I nitial C ombination T herapy for T ype 2 D iabetes ( EDICT ): a randomized trial

Diabetes, obesity & metabolism, 2015-03, Vol.17 (3), p.268-275

2015

Volltextzugriff (PDF)

Dose-Response Effect of a Single Administration of Oral Hexyl-Insulin Monoconjugate 2 in Healthy Nondiabetic Subjects

Diabetes care, 2004-12, Vol.27 (12), p.2868-2873

2004

Volltextzugriff (PDF)

Effects of Insulin and Oral Antidiabetic Agents on Glucose Metabolism, Vascular Dysfunction and Skeletal Muscle Inflammation in Type 2 Diabetic Subjects

Diabetes/metabolism research and reviews, 2011-05, Vol.27 (4), p.373-382

2011

Volltextzugriff (PDF)

Rosiglitazone decreases albuminuria in type 2 diabetic patients. Commentary

Kidney international, 2007, Vol.72 (11)

2007

Volltextzugriff (PDF)

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

Diabetes care, 2022-08, Vol.45 (8), p.1707-1708

2022

Volltextzugriff (PDF)

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

Diabetes (New York, N.Y.), 2022-08, Vol.71 (8), p.1601-1602

2022

Volltextzugriff (PDF)

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

Diabetes care, 2010-05, Vol.33 (5), p.951-957

2010

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(30)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Endocrinology & Metabolism
(13)
Humans
(12)
Diabetes
(10)
Diabetes Mellitus, Type 2 - Drug Therapy
(9)
Female
(9)
Insulin Resistance
(9)
Male
(9)
Middle Aged
(9)
Hypoglycemic Agents - Therapeutic Use
(8)
Biological And Medical Sciences
(7)
Insulin
(7)
Medical Sciences
(7)
Diabetes Mellitus, Type 2 - Metabolism
(6)
Diabetes. Impaired Glucose Tolerance
(6)
Endocrine Pancreas. Apud Cells
(6)
Endocrinopathies
(6)
Glucose Clamp Technique
(6)
Adult
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial

Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes

Rosiglitazone decreases albuminuria in type 2 diabetic patients

Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects

O1 Mode d’action de l’exénatide sur la réduction des glycémies post-prandiales dans le diabète de type 2

Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

Exenatide Exerts Its Positive Effects on Liver by Reducing both Hepatic and Adipose Tissue Insulin Resistance

Metabolic effects of muraglitazar in type 2 diabetic subjects

Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects

Insulin Secretion is a Strong Predictor for Need of Insulin Therapy in Patients With New Onset Diabetes and HbA1c >10%, a post hoc analysis of EDICT study

T2DM Subgroups and Response to Glucose-lowering Therapy: Results from EDICT and Qatar Study

Stoffwechselvorgänge beim Anstieg der Ketonkörper im Plasma unter Dapagliflozin

Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus

PS072 - Exenatide Exerts Its Positive Effects on Liver by Reducing both Hepatic and Adipose Tissue Insulin Resistance

T2DM Subgroups and Response to Glucose-lowering Therapy: Results from EDICT and Qatar Study

New and Emerging Therapies for Type 2 Diabetes

Incretin Mimetics and Dipeptidyl Peptidase-IV Inhibitors: Potential New Therapies for Type 2 Diabetes Mellitus

Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the E fficacy and D urability of I nitial C ombination T herapy for T ype 2 D iabetes ( EDICT ): a randomized trial

Dose-Response Effect of a Single Administration of Oral Hexyl-Insulin Monoconjugate 2 in Healthy Nondiabetic Subjects

Effects of Insulin and Oral Antidiabetic Agents on Glucose Metabolism, Vascular Dysfunction and Skeletal Muscle Inflammation in Type 2 Diabetic Subjects

Rosiglitazone decreases albuminuria in type 2 diabetic patients. Commentary

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

A Special Thanks to Lyn Reynolds, Director of the ADA Editorial Office, as She Embarks on Her Retirement

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

Suchergebnisse filtern